about
Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAsHealth-related quality of life in Hodgkin lymphoma: a systematic reviewThe evolving role of response-adapted PET imaging in Hodgkin lymphomaThe role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage diseaseAllogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older PatientsParadoxical regulation of hypoxia inducible factor-1α (HIF-1α) by histone deacetylase inhibitor in diffuse large B-cell lymphomaImmunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)The genetic landscape of mutations in Burkitt lymphoma.TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology.Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectTime to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanismsMitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculataBurkitt's and Burkitt-like lymphoma.The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphomaPeripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyTreatment of T-cell non-Hodgkin's lymphoma.Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) ProjectProton irradiation impacts age-driven modulations of cancer progression influenced by immune system transcriptome modifications from splenic tissueClinical characteristics of erythropoietin-associated pure red cell aplasia.Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group.The Research on Adverse Drug Events and Reports (RADAR) project.Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies.Oxidative stress and apoptosis: a new treatment paradigm in cancer.A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma.The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks.Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.Genetic heterogeneity of diffuse large B-cell lymphomaParaneoplastic pyoderma gangrenosum with posttransplant lymphoproliferative disorder.Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project.De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
P50
Q24618086-225A73DE-6613-4CFE-9251-E88015290711Q26740480-EDC86774-A964-445D-90DD-38A3319E880CQ26750993-168C2D74-9F60-4D4E-A9CC-E136C0DEF31EQ26858893-075DD557-7704-4CFF-BCC1-38940666407DQ28066710-1BF0A131-D327-432F-AEB2-09B409E73443Q28535447-3BDF1894-D635-4694-A154-3AEA2F9F9F16Q30303110-D07B29B5-FEB9-43A2-AF46-717CE2FF9C20Q30453771-B600931F-97B2-4BF3-B763-7152F6FEFCF2Q33344550-8112AF7F-12D8-4C0B-9FC8-60FF2B5CC61CQ33373051-A9848BEC-E769-46BE-827C-E7994964CE61Q33383576-D09E56CF-0F2F-4D4B-B29A-DD2ADA63A7BEQ33387817-0ED9C6B0-5021-4A4F-9AD9-DDE95E985BB0Q33402885-E3A8432B-A0F1-4B81-A891-2D2E2A13EDF1Q33409608-3B5BEF50-235D-4F35-B702-D9674C17D0C0Q33411059-7071E407-B13F-4034-8CEE-2D7990300F4FQ33426847-2EF34144-5B48-40BF-B9CF-EA183BFBFD24Q33428066-271A4B9A-CD79-42FE-A722-833919A1F40DQ33710720-BB70633D-608E-4989-A387-7BB2EA42C575Q34020461-5960B935-9159-4409-BFAD-B2704F59938FQ34168689-E148CA93-464D-4A34-B088-FEAA73CAE6DEQ34696338-B76E25D4-BBF1-426F-A3C3-E1DC6AFD4F23Q34802502-E2C6457B-F141-464F-AA2C-F24C8CD94E6FQ34860750-D9A3A314-6C00-4FB4-A202-F17C97EAB542Q35140947-1138C965-4069-428A-A121-459BD4CE3E2FQ35784338-E94E4C3F-9795-4F5F-9233-07661C978929Q35826477-68201115-623E-4174-ADE8-3A2ECC812839Q35847694-D8C51DE2-15D8-4D66-8DEC-4787FA709589Q36078666-B24610D5-478B-4A08-9A8F-0E76B424803BQ36081193-C2CAB09C-3F4D-46AE-B7A3-D8E9EE7A33D5Q36081202-E299EA47-FDAF-4E43-9FE5-4A3EDC0D6531Q36115860-7F43DB1B-3C4C-4865-A28E-475F2A99573DQ36168706-167113AD-A09E-468C-9644-DCD025D963CCQ36250951-F7989E29-3B3B-474D-9C67-8A590C9ADED4Q36255792-62A48888-5A40-4C63-BD40-D78EE3EBF5F4Q36365020-BF73F4A2-3399-43E3-8097-9177063DEEA3Q36481536-32EDF8A2-14AE-4364-A85B-0EFE062EE3F5Q36567845-8D12F831-4E1E-4ABE-90E8-E6B68EEF4F59Q36798703-D38608F2-EF5A-4F43-98E2-B5AF48D5906AQ36847551-BD5A8F18-784E-45BC-A35A-8FE90ADF46BBQ36928813-11FB272A-4BF8-471E-A3A4-31AA77C5FACB
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrew M Evens
@ast
Andrew M Evens
@en
Andrew M Evens
@es
Andrew M Evens
@nl
Andrew M Evens
@sl
type
label
Andrew M Evens
@ast
Andrew M Evens
@en
Andrew M Evens
@es
Andrew M Evens
@nl
Andrew M Evens
@sl
prefLabel
Andrew M Evens
@ast
Andrew M Evens
@en
Andrew M Evens
@es
Andrew M Evens
@nl
Andrew M Evens
@sl
P106
P21
P31
P496
0000-0002-6900-1824
P569
2000-01-01T00:00:00Z